Welcome to our dedicated page for Maravai Lifesciences Holdings news (Ticker: MRVI), a resource for investors and traders seeking the latest updates and insights on Maravai Lifesciences Holdings stock.
Maravai Lifesciences Holdings Inc. (MRVI) provides essential tools for breakthrough therapies and diagnostics through its nucleic acid production and biologics safety testing solutions. This news hub offers investors and industry professionals direct access to verified updates about the company's scientific advancements and strategic developments.
Track MRVI's latest financial results, manufacturing innovations, and partnership announcements in one centralized location. Our curated news collection helps stakeholders monitor regulatory milestones, technology licensing agreements, and capacity expansion initiatives critical to the life sciences sector.
Key updates include earnings disclosures, facility certifications, reagent production scaling efforts, and quality control advancements. Users will find information about Maravai's GMP-grade oligonucleotides, CLIA-certified testing services, and contributions to cell/gene therapy development pipelines.
Bookmark this page for real-time access to Maravai's progress in enabling precision medicine and vaccine development. Check regularly for objective reporting on their role in supporting biopharmaceutical research and diagnostic innovation worldwide.
TriLink BioTechnologies (NASDAQ: MRVI) has launched its first mRNA synthesis kit featuring CleanCap® capping technology. The all-in-one in vitro transcription (IVT) kit delivers up to 2X more mRNA yield and up to 85% lower dsRNA compared to market alternatives. The kit includes CleanCap® AG (3′ OMe), CleanScribe™ RNA Polymerase, nucleotides with N1-methylpseuouridine, and CleanScript® IVT.
To celebrate the launch, TriLink is donating ten kits each to seven academic institutions across the U.S. and Europe, including Houston Methodist Research Institute, UC San Diego, University Medical Center Utrecht, University of Oxford, and Yale School of Medicine. The donated kits can yield up to a combined 250mg of capped mRNAs.
The kit features CleanCap AG (3′ OMe) with over 95% capping efficiency for improved protein expression, streamlining mRNA manufacturing with fewer steps compared to traditional ARCA or enzymatic methods.
TriLink BioTechnologies, a Maravai LifeSciences company (NASDAQ: MRVI), has signed a Memorandum of Understanding (MOU) with the International Vaccine Institute (IVI) to advance mRNA-based vaccine development. The collaboration aims to develop vaccines using mRNA technologies, facilitate knowledge exchange, and support joint scientific initiatives, with a focus on improving access in low- and middle-income countries (LMICs).
TriLink's CleanCap® technology, launched in 2017, is currently used in most approved COVID-19 mRNA and saRNA vaccines. In 2024, the company expanded its offerings with IVT enzymes and opened a GMP manufacturing facility in San Diego. IVI, established in 1997 in Seoul, focuses on developing vaccines for diseases affecting LMICs, including cholera, typhoid, chikungunya, and COVID-19.
Maravai LifeSciences (NASDAQ: MRVI), a global provider of life science reagents and services, has scheduled its first quarter 2025 financial results announcement for Monday, May 12, 2025, after market close. The company will host a conference call and webcast at 2:00 p.m. PT/ 5:00 p.m. ET on the same day.
Participants can join the conference call by dialing (800) 343-4849 or (203) 518-9848 and referencing Conference ID MARAVAI. The event will also be accessible via webcast through the "Investors" section of Maravai's website.
Maravai LifeSciences Holdings (NASDAQ:MRVI) faces a significant class action lawsuit following concerning financial disclosures. On February 25, 2025, the company announced delays in its earnings release and annual report, citing issues with revenue recognition and potential impairment charges. This announcement triggered a 21.7% drop in stock price.
The lawsuit, filed in the U.S. District Court for the Southern District of California, alleges that Maravai misled investors about its financial condition during the period between August 7, 2024, and February 24, 2025. Key allegations include undisclosed weaknesses in internal financial controls, improper revenue recording, inflated goodwill valuation, and misleading statements about growth prospects.
Affected investors who experienced financial losses have until May 5, 2025, to apply for lead plaintiff status in the legal proceedings.
Maravai LifeSciences (NASDAQ:MRVI) faces a significant class action lawsuit following troubling financial disclosures. On February 25, 2025, the company delayed its earnings release and annual report, triggering a 21.7% stock price decline.
The lawsuit, filed in the U.S. District Court for the Southern District of California, alleges that Maravai misled investors between August 7, 2024, and February 24, 2025. Key allegations include failure to disclose weak internal financial controls, improper revenue recognition, overstated goodwill valuation, and misleading statements about growth potential.
Affected investors who purchased MRVI shares during the specified period have until May 5, 2025, to seek lead plaintiff status. The case is being handled by Cohen Milstein, a firm noted for securing a $1 billion recovery in the Wells Fargo litigation in 2024.
Maravai LifeSciences (NASDAQ:MRVI) faces a securities class action lawsuit filed in the U.S. District Court for the Southern District of California. The lawsuit covers investors who purchased shares between August 7, 2024, and February 24, 2025, with a lead plaintiff deadline of May 5, 2025.
The legal action alleges violations of Securities Exchange Act Sections 10(b) and 20(a), claiming the company and senior executives misled investors about:
- Inadequate financial controls, especially in revenue recognition
- Incorrect revenue reporting for key transactions in fiscal 2024
- Overstated goodwill valuation
- Misrepresentation of financial condition and growth potential
On February 25, 2025, Maravai delayed its earnings release and annual report due to revenue recognition concerns and a potential non-cash impairment charge, resulting in a 21.7% stock price decline.
Maravai LifeSciences (NASDAQ:MRVI) faces a securities class action lawsuit filed in the U.S. District Court for the Southern District of California. The lawsuit covers investors who purchased shares between August 7, 2024, and February 24, 2025.
The complaint alleges that Maravai and senior executives made false and misleading statements regarding:
- Financial controls and revenue recognition policies
- Improper revenue recording in fiscal 2024
- Overstated goodwill valuation
- Misrepresented financial condition and growth prospects
On February 25, 2025, Maravai announced delays in its earnings release and annual report due to revenue recognition concerns and a potential non-cash impairment charge. The stock subsequently dropped 21.7%. Affected investors have until May 5, 2025, to file for lead plaintiff status in the case.
Maravai LifeSciences (NASDAQ: MRVI) has postponed its previously announced Q4 and full year 2024 earnings release and conference call originally scheduled for February 25, 2025. The company will file a Form 12b-25 with the SEC to delay its annual 10-K report for the fiscal year ended December 31, 2024.
Maravai intends to hold the postponed earnings call and file the 2024 Form 10-K by March 18, 2025, before the expiration of the automatic 15-day extension from the original March 3, 2025 due date.
The delay is attributed to three main factors: (1) additional time needed to assess a potential non-cash goodwill impairment charge related to the Alphazyme acquisition; (2) assessment of a revenue recognition error involving approximately $3.9 million recorded in Q2 2024 that should have been recorded in Q3 2024; and (3) time required to complete assessment of disclosure controls and internal controls over financial reporting, including remediation of a material weakness in revenue recognition controls.
Despite these issues, Maravai still expects full-year 2024 revenue to be near the mid-point of its previously announced guidance range of $255.0-265.0 million.
Maravai LifeSciences (NASDAQ: MRVI) has completed its acquisition of Officinae Bio's DNA and RNA business. This acquisition integrates Officinae Bio's AI-enabled mRNA design platforms with Maravai and TriLink BioTechnologies' drug substance manufacturing capabilities, offering comprehensive expertise and novel technologies. This integration aims to accelerate the mRNA sequence-optimization phase and advance clinical testing and commercial manufacturing.
Officinae Bio, based in Venice, Italy, uses a proprietary digital platform to speed up mRNA drug candidate prototyping, facilitating rapid testing of diverse combinations of capping analogs, chemical modifications, and sequence designs. The acquisition will enhance Maravai's capabilities in next-generation medicines, particularly in mRNA and CRISPR, leveraging proprietary technologies like CleanCap® analogs.
This move also marks Maravai's entry into the European market with a manufacturing footprint, expected to drive growth across multiple product lines. Officinae Bio's CEO, Davide De Lucrezia, will continue to lead the team within Maravai’s Nucleic Acid Production segment.
FAQ
What is the current stock price of Maravai Lifesciences Holdings (MRVI)?
What is the market cap of Maravai Lifesciences Holdings (MRVI)?
